Immunome Net Income From Continuing Ops vs Research Development Analysis

IMNM Stock

USD 9.82 0.40 4.25%

Immunome financial indicator trend analysis is infinitely more than just investigating Immunome recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunome is a good investment. Please check the relationship between Immunome Net Income From Continuing Ops and its Research Development accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.

Net Income From Continuing Ops vs Research Development

Net Income From Continuing Ops vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunome Net Income From Continuing Ops account and Research Development. At this time, the significance of the direction appears to have pay attention.

The correlation between Immunome's Net Income From Continuing Ops and Research Development is -0.99. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Research Development in the same time period over historical financial statements of Immunome, assuming nothing else is changed. The correlation between historical values of Immunome's Net Income From Continuing Ops and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of Immunome are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Net Income From Continuing Ops i.e., Immunome's Net Income From Continuing Ops and Research Development go up and down completely randomly.

Correlation Coefficient

-0.99

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Net Income From Continuing Ops

Research Development

Most indicators from Immunome's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunome current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.At this time, Immunome's Selling General Administrative is very stable compared to the past year. As of the 24th of November 2024, Enterprise Value is likely to grow to about 121.1 M, while Issuance Of Capital Stock is likely to drop about 29.1 K.

	2020	2023	2024 (projected)
Depreciation And Amortization	755K	728K	736.1K
Interest Income	1K	2.7M	2.9M

Depreciation And Amortization Interest Income

Immunome fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt
Total Assets		0.03	0.78	0.98	0.98	-0.69	0.61	0.33	-0.99	-0.96	0.77	0.99	0.36	-0.62	-0.67	-0.64	1.0	0.85	-0.62	0.76	0.79	0.97	-0.37	0.98	0.94	0.67
Short Long Term Debt Total	0.03		-0.23	0.0	-0.09	0.25	-0.51	0.91	0.06	0.03	-0.32	-0.06	0.9	-0.18	-0.47	0.6	0.03	-0.15	0.47	0.55	-0.15	0.0	0.63	-0.09	0.26	-0.36
Other Current Liab	0.78	-0.23		0.83	0.83	-0.62	0.78	0.05	-0.84	-0.84	0.99	0.81	0.11	-0.16	-0.14	-0.74	0.78	0.94	-0.79	0.42	0.77	0.78	-0.5	0.83	0.66	0.88
Total Current Liabilities	0.98	0.0	0.83		0.96	-0.62	0.58	0.3	-0.96	-0.98	0.81	0.97	0.34	-0.51	-0.57	-0.63	0.98	0.86	-0.61	0.78	0.73	0.97	-0.34	0.96	0.93	0.65
Total Stockholder Equity	0.98	-0.09	0.83	0.96		-0.8	0.75	0.21	-0.99	-0.95	0.84	0.99	0.23	-0.56	-0.59	-0.7	0.98	0.9	-0.76	0.65	0.86	0.96	-0.53	1.0	0.87	0.78
Other Liab	-0.69	0.25	-0.62	-0.62	-0.8		-0.89	0.06	0.76	0.64	-0.68	-0.75	0.08	0.39	0.4	0.58	-0.69	-0.74	0.92	-0.21	-0.89	-0.7	0.86	-0.8	-0.45	-0.84
Net Tangible Assets	0.61	-0.51	0.78	0.58	0.75	-0.89		-0.31	-0.72	-0.58	0.84	0.7	-0.3	-0.18	-0.1	-0.74	0.61	0.78	-0.97	0.01	0.84	0.59	-0.88	0.75	0.38	0.93
Property Plant And Equipment Net	0.33	0.91	0.05	0.3	0.21	0.06	-0.31		-0.25	-0.29	-0.04	0.25	0.99	-0.48	-0.69	0.22	0.34	0.19	0.28	0.69	0.17	0.31	0.55	0.21	0.49	-0.08
Net Debt	-0.99	0.06	-0.84	-0.96	-0.99	0.76	-0.72	-0.25		0.95	-0.84	-1.0	-0.27	0.59	0.61	0.71	-0.99	-0.9	0.72	-0.66	-0.86	-0.96	0.47	-0.99	-0.89	-0.76
Retained Earnings	-0.96	0.03	-0.84	-0.98	-0.95	0.64	-0.58	-0.29	0.95		-0.83	-0.95	-0.33	0.52	0.56	0.68	-0.96	-0.9	0.65	-0.73	-0.78	-0.99	0.37	-0.95	-0.86	-0.71
Accounts Payable	0.77	-0.32	0.99	0.81	0.84	-0.68	0.84	-0.04	-0.84	-0.83		0.82	0.02	-0.15	-0.12	-0.77	0.77	0.94	-0.85	0.35	0.79	0.77	-0.59	0.84	0.62	0.91
Cash	0.99	-0.06	0.81	0.97	0.99	-0.75	0.7	0.25	-1.0	-0.95	0.82		0.27	-0.6	-0.63	-0.69	0.99	0.88	-0.7	0.68	0.83	0.96	-0.46	0.99	0.9	0.73
Non Current Assets Total	0.36	0.9	0.11	0.34	0.23	0.08	-0.3	0.99	-0.27	-0.33	0.02	0.27		-0.42	-0.64	0.22	0.36	0.22	0.26	0.73	0.16	0.34	0.55	0.23	0.53	-0.07
Non Currrent Assets Other	-0.62	-0.18	-0.16	-0.51	-0.56	0.39	-0.18	-0.48	0.59	0.52	-0.15	-0.6	-0.42		0.92	0.47	-0.63	-0.42	0.12	-0.45	-0.58	-0.6	-0.01	-0.56	-0.57	-0.24
Other Assets	-0.67	-0.47	-0.14	-0.57	-0.59	0.4	-0.1	-0.69	0.61	0.56	-0.12	-0.63	-0.64	0.92		0.21	-0.68	-0.39	0.08	-0.68	-0.52	-0.65	-0.08	-0.6	-0.69	-0.16
Long Term Debt	-0.64	0.6	-0.74	-0.63	-0.7	0.58	-0.74	0.22	0.71	0.68	-0.77	-0.69	0.22	0.47	0.21		-0.64	-0.8	0.69	-0.06	-0.77	-0.65	0.53	-0.7	-0.41	-0.79
Cash And Short Term Investments	1.0	0.03	0.78	0.98	0.98	-0.69	0.61	0.34	-0.99	-0.96	0.77	0.99	0.36	-0.63	-0.68	-0.64		0.85	-0.62	0.76	0.79	0.98	-0.36	0.98	0.94	0.66
Common Stock Shares Outstanding	0.85	-0.15	0.94	0.86	0.9	-0.74	0.78	0.19	-0.9	-0.9	0.94	0.88	0.22	-0.42	-0.39	-0.8	0.85		-0.8	0.45	0.92	0.87	-0.51	0.9	0.68	0.92
Non Current Liabilities Total	-0.62	0.47	-0.79	-0.61	-0.76	0.92	-0.97	0.28	0.72	0.65	-0.85	-0.7	0.26	0.12	0.08	0.69	-0.62	-0.8		-0.08	-0.84	-0.65	0.91	-0.76	-0.37	-0.94
Capital Lease Obligations	0.76	0.55	0.42	0.78	0.65	-0.21	0.01	0.69	-0.66	-0.73	0.35	0.68	0.73	-0.45	-0.68	-0.06	0.76	0.45	-0.08		0.31	0.74	0.17	0.65	0.89	0.13
Other Current Assets	0.79	-0.15	0.77	0.73	0.86	-0.89	0.84	0.17	-0.86	-0.78	0.79	0.83	0.16	-0.58	-0.52	-0.77	0.79	0.92	-0.84	0.31		0.81	-0.63	0.86	0.57	0.92
Other Stockholder Equity	0.97	0.0	0.78	0.97	0.96	-0.7	0.59	0.31	-0.96	-0.99	0.77	0.96	0.34	-0.6	-0.65	-0.65	0.98	0.87	-0.65	0.74	0.81		-0.4	0.96	0.87	0.69
Total Liab	-0.37	0.63	-0.5	-0.34	-0.53	0.86	-0.88	0.55	0.47	0.37	-0.59	-0.46	0.55	-0.01	-0.08	0.53	-0.36	-0.51	0.91	0.17	-0.63	-0.4		-0.53	-0.09	-0.74
Net Invested Capital	0.98	-0.09	0.83	0.96	1.0	-0.8	0.75	0.21	-0.99	-0.95	0.84	0.99	0.23	-0.56	-0.6	-0.7	0.98	0.9	-0.76	0.65	0.86	0.96	-0.53		0.87	0.78
Property Plant And Equipment Gross	0.94	0.26	0.66	0.93	0.87	-0.45	0.38	0.49	-0.89	-0.86	0.62	0.9	0.53	-0.57	-0.69	-0.41	0.94	0.68	-0.37	0.89	0.57	0.87	-0.09	0.87		0.42
Short Long Term Debt	0.67	-0.36	0.88	0.65	0.78	-0.84	0.93	-0.08	-0.76	-0.71	0.91	0.73	-0.07	-0.24	-0.16	-0.79	0.66	0.92	-0.94	0.13	0.92	0.69	-0.74	0.78	0.42

Click cells to compare fundamentals

Immunome Account Relationship Matchups

Immunome fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	5.1M	44.5M	57.9M	24.0M	148.5M	156.0M
Short Long Term Debt Total	564K	613K	317K	293K	1.7M	845.7K
Other Current Liab	666K	1.4M	6.3M	4.7M	7.7M	3.9M
Total Current Liabilities	1.7M	3.0M	9.7M	7.3M	21.8M	22.9M
Total Stockholder Equity	(35.6M)	41.3M	48.2M	16.7M	119.9M	125.9M
Net Tangible Assets	(35.6M)	41.3M	48.2M	16.7M	19.2M	10.0M
Property Plant And Equipment Net	1.7M	1.5M	855K	965K	3.6M	2.0M
Net Debt	(2.0M)	(39.2M)	(48.9M)	(20.0M)	(97.0M)	(92.2M)
Retained Earnings	(36.6M)	(54.4M)	(79.1M)	(116.0M)	(222.8M)	(211.7M)
Accounts Payable	548K	1.2M	3.1M	2.4M	3.3M	2.0M
Cash	2.5M	39.8M	49.2M	20.3M	98.7M	103.6M
Non Current Assets Total	1.9M	1.6M	1.3M	1.4M	3.8M	2.3M
Cash And Short Term Investments	2.5M	39.8M	49.2M	20.3M	138.1M	145.0M
Common Stock Shares Outstanding	5.7M	10.1M	11.5M	12.1M	19.8M	11.7M
Liabilities And Stockholders Equity	5.1M	44.5M	57.9M	24.0M	148.5M	156.0M
Non Current Liabilities Total	39.0M	142K	12K	62K	6.8M	9.9M
Capital Lease Obligations	239K	0.0	317K	293K	1.7M	1.7M
Other Current Assets	579K	5.4M	2.6M	2.9M	6.3M	3.4M
Other Stockholder Equity	927K	95.7M	69.4M	132.7M	342.7M	359.8M
Total Liab	40.7M	3.2M	9.7M	7.4M	28.7M	15.9M
Net Invested Capital	(35.3M)	42.0M	48.2M	16.7M	119.9M	125.9M
Property Plant And Equipment Gross	1.7M	1.5M	3.9M	681K	7.5M	7.9M
Total Current Assets	3.1M	42.9M	56.6M	22.6M	144.7M	151.9M
Accumulated Other Comprehensive Income	(38.9M)	(44.5M)	(57.9M)	0.0	22K	23.1K
Net Working Capital	1.5M	39.9M	46.9M	15.3M	122.9M	129.0M
Short Term Debt	451K	479K	317K	229K	310K	319.7K
Property Plant Equipment	1.7M	1.5M	855K	681K	612.9K	1.1M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Immunome is a strong investment it is important to analyze Immunome's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Immunome's future performance. For an informed investment choice regarding Immunome Stock, refer to the following important reports:

How To Invest In Immunome

Details

Is Immunome Stock a good investment?

Details

What is Immunome's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.

You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(7.94)

Revenue Per Share

0.189

Quarterly Revenue Growth

(0.18)

Return On Assets

(0.40)

Return On Equity

(2.76)

The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immunome Net Income From Continuing Ops vs Research Development Analysis

Net Income From Continuing Ops vs Research Development

Net Income From Continuing Ops vs Research Development Correlation Analysis

Correlation Coefficient

Net Income From Continuing Ops

Research Development

Immunome fundamental ratios Correlations

Immunome Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immunome fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash	+ 0.99	Total Assets
Accounts Payable	+ 0.99	Other Current Liab
Cash	+ 0.99	Total Stockholder Equity
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.99	Retained Earnings
Net Invested Capital	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Debt	- 0.99	Total Assets